Atara Biotherapeutics (ATRA) Net Cash Flow Growth (3y) (2016 - 2026)
Atara Biotherapeutics (ATRA) Net Cash Flow Growth (3y) (2016 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCF Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | -50.33% |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 38.47% |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 33.37% |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | -29.82% |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | - |
| 10 | Atara Biotherapeutics | 110.04 Mn | 101.68 Mn | 392,000.00 | 85.97% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 85.97% |
| Dec 31, 2025 | -53.14% |
| Sep 30, 2025 | -26.04% |
| Jun 30, 2025 | 27.94% |
| Mar 31, 2025 | -35.85% |
| Dec 31, 2024 | -44.33% |
| Sep 30, 2024 | 50.69% |
| Jun 30, 2024 | 48.26% |
| Mar 31, 2024 | 29.81% |
| Dec 31, 2023 | -31.67% |
| Sep 30, 2023 | 53.10% |
| Jun 30, 2023 | -38.56% |
| Mar 31, 2023 | -120.66% |
| Dec 31, 2022 | 49.24% |
| Sep 30, 2022 | -29.23% |
| Jun 30, 2022 | -131.20% |
| Mar 31, 2022 | 0.50% |
| Dec 31, 2021 | -10.16% |
| Sep 30, 2021 | 34.08% |
| Jun 30, 2021 | -60.62% |